

Antidotes for poisoning by alcohols that form toxic metabolites

Kenneth McMartin,¹ Dag Jacobsen² & Knut Erik Hovda³

¹Department of Pharmacology, Toxicology & Neuroscience, Louisiana State University Health Sciences Center – Shreveport, 1501 Kings Highway, Shreveport, Louisiana, 71130-3932 USA,

²Department of Acute Medicine, Division of Medicine, Oslo University Hospital, NO-0424 Oslo, Norway and ³The Norwegian CBRNe Centre of Medicine, Department of Acute Medicine, Division of Medicine, Oslo University Hospital, NO-0424 Oslo, Norway

Correspondence

Dr Kenneth McMartin, Ph.D., Department of Pharmacology, Toxicology & Neuroscience, Louisiana State University Health Sciences Center – Shreveport, 1501 Kings Highway, Shreveport, Louisiana, 71130-3932 USA.

Tel.: +1 31 8675 7871

Fax: +1 31 8675 7857

E-mail: kmcmar@lsuhsc.edu

Keywords

diethylene glycol, ethanol, ethylene glycol, fomepizole, methanol

Received

22 June 2015

Accepted

3 November 2015

Accepted Article Published Online

9 November 2015

The alcohols, **methanol**, **ethylene glycol** and diethylene glycol, have many features in common, the most important of which is the fact that the compounds themselves are **relatively non-toxic** but are **metabolized**, initially **by alcohol dehydrogenase**, to various **toxic intermediates**. These compounds are readily available worldwide in commercial products as well as in homemade alcoholic beverages, both of which lead to most of the poisoning cases, from either unintentional or intentional ingestion. Although relatively infrequent in overall occurrence, poisonings by metabolically-toxic alcohols do unfortunately occur in outbreaks and can result in severe morbidity and mortality. These poisonings have traditionally been treated with ethanol since it competes for the active site of alcohol dehydrogenase and decreases the formation of toxic metabolites. Although ethanol can be effective in these poisonings, there are substantial practical problems with its use and so **fomepizole**, a potent **competitive inhibitor** of **alcohol dehydrogenase**, was developed for a hopefully better treatment for metabolically-toxic alcohol poisonings. Fomepizole has **few side effects** and is easy to use in practice and it **may obviate** the need for **haemodialysis** in some, but not all, patients. Hence, fomepizole has largely replaced ethanol as the toxic alcohol antidote in many countries. Nevertheless, ethanol remains an important alternative because access to fomepizole can be limited, the cost may appear excessive, or the physician may prefer ethanol due to experience.

Introduction

Among the alcohols with a short carbon chain ending with one (alcohol) or two (glycol) hydroxyl groups, there is a subset of compounds that are related by a similar toxic mode of action. While other alcohols such as **ethanol** and isopropanol produce their **toxicity** through the **alcohol moiety**, this subset produces **acidic metabolites** which are **toxic** and result in similar clinical features. In this review, this subset is denoted as the metabolically-toxic alcohols and includes **ethylene glycol**, **methanol** and diethylene glycol. Some glycol ethers are also metabolized to intermediates, but their poisonings are less severe with few common features, so are not discussed.

The presence of **methanol**, **ethylene glycol** and diethylene glycol worldwide in readily available commercial products such as **antifreeze**, **windshield-washer fluid** and fuel additives leads to most poisoning cases, often resulting in severe morbidity and mortality. **Methanol** poisoning is associated with visual disturbances or **blindness**

and with **basal ganglion** lesions, both can be **permanent** in survivors [1, 2]. The glycols are associated with **acute kidney injury**, which can lead to **irreversible kidney failure** [3–5] and to severe neurological damage [6]. Definitive analytical **tests** are **not** readily **available** and **diagnosis** is therefore often attempted with **imperfect surrogate tests** such as osmolar gap and blood gases [7]. **Delayed diagnosis** and treatment are the main reasons for **poor outcomes** in these patients that otherwise **should have little mortality** because **early diagnosis** normally leads to **successful treatment** [8, 9]. Hopefully, simpler bedside methods will be available in the near future [10]. The **treatment** of these poisonings consists of **bicarbonate** to reverse the metabolic acidosis, **alcohol dehydrogenase (ADH) inhibition** by either ethanol or **fomepizole**, and **haemodialysis** to enhance the **elimination** of the alcohols and their metabolites. This review will discuss the differing roles of the ADH inhibitors as antidotes for these poisonings, as well as circumstances in which either is used alone or combined with dialysis.

Epidemiology of toxic alcohol ingestions

Poisonings with **metabolically-toxic** alcohols occur for many reasons, including substitution ingestions due to reduced ethanol availability, suicidal attempts, unintentional ingestions when commercial product is put into other containers or when beverages or medications are illicitly adulterated. Table 1 shows an estimate of the frequency of exposures to these substances for 2013 in the United States National Poison Data System (NPDS) report [11]. These numbers have been relatively stable over the last 20 years based on similar numbers for 1987 [12]. In general, exposures to ethylene glycol are the most common, followed by methanol, with diethylene glycol (as brake fluid) being relatively rare. NPDS data represents reports of 'exposures' and may over-report the numbers. Good data on the frequency of these poisonings elsewhere worldwide is not available, although recent outbreaks of methanol poisoning are accessible (http://www.oslo-universitetssykehus.no/omoss/_avdelinger/_akuttmedisinsk/_Documents/outbreaks%20new%20table%20combined.pdf [13]).

Methanol

Although methanol poisoning can occur as an isolated ingestion, it is infamous for being involved in numerous epidemics. In outbreaks, methanol poisoning usually results from consumption of **alcoholic beverages that have been spiked with methanol** due to its low cost. These epidemics occur world-wide, often with **high mortality** rates [14–20].

Ethylene glycol

Most cases of ethylene glycol poisoning occur through the ingestion of **antifreeze** by individuals, as an alcohol substitute, with the intention of self-harm [21], or for homicidal purposes (<http://www.usatoday.com/story/news/nation/2013/06/23/antifreeze-deaths/2449915/> [22]). Epidemics

of ethylene glycol poisoning have occurred very rarely [23, 24], usually as copy-cat intentional (suicidal) ingestions.

Diethylene glycol

Individual diethylene glycol poisonings are rare (Table 1), but may occur in epidemics, mostly due to illicit or uninformed substitution of diethylene glycol as a solvent in liquid medications for more expensive and less toxic propylene glycol or glycerine [25]. In the United States in 1937, diethylene glycol was the solvent in a sulfanilamide elixir leading to the deaths of 105 individuals and to passage of the 1938 Federal Food, Drug and Cosmetic Act, which required that all components of a drug product be demonstrated as safe prior to marketing. Subsequent epidemics have occurred [26] worldwide, such as in Haiti in 1995 when 88 of 98 children died who consumed a DEG-contaminated medication [27] and in Panama in 2006 where there were an estimated minimum of 78 deaths out of 119 reported as having consumed a DEG-contaminated cough syrup [28].

Clinical course of these toxicities

Methanol and **ethylene glycol** poisonings **share** many clinical and biochemical features, including metabolite-induced **metabolic acidosis**. The **latent period** from **intake to symptoms** (given no concomitant ethanol intake) is typically **6–12 h** for **ethylene glycol** and **12–24 h** for **methanol**, at which time, metabolic acidosis develops. Subsequently, **ethylene glycol** patients will develop acute **kidney injury**, **coma**, **seizures** and **cardiovascular failure** [29]. **Oxalate crystals** in the **urine** can be observed with increased frequency **after 6 h** [30]. **Methanol-poisoned** victims usually report **visual disturbances**, **gastrointestinal symptoms**, **chest pain** and **dyspnoea**. Pseudopapillitis can often be seen after 12–24 h [29, 31].

Diethylene glycol poisonings often present in three different phases: the first phase is characterized with GI symptoms, along with metabolic acidosis. After 1 to 3 days, acute kidney injury develops. Lack of specific treatment can lead to death in this phase. If patients survive and reach the final stage (after about 5–7 days), neurological features may occur, including bilateral facial nerve palsy and peripheral neuropathy leading to paralysis, quadriplegia, coma and death [26].

Mechanism of toxicity of toxic alcohols

None of the three compounds is very acutely **toxic** by **itself** [32, 33] and they must be **metabolized** to **toxic intermediates**, which takes place through oxidations by **ADH** and **aldehyde dehydrogenase** (Figure 1). The initial acidic metabolites lead to metabolic acidosis, whereas

Table 1

Exposures to metabolically-toxic alcohols in the United States in 2013* [11]

	Total exposures	Treated in health care facility	Fatalities
Methanol	1578	616	8
Ethylene glycol	5956	2314	16
Brake fluid†	882	339	2
Methanol – 1987‡ [12]	1601	852	6
Ethylene glycol – 1987‡ [12]	4543	1403	11

*Data from the 2013 US National Poison Data System report [11] unless indicated. †NPDS report does not produce numbers on DEG directly but brake fluids contain a high concentration of DEG among other solvents. ‡1987 report for comparison with 2013 numbers [12].




Figure 1

Metabolism of methanol, ethylene glycol and diethylene glycol. The metabolism of the three alcohols to their major toxic metabolites are displayed. Not shown are the branch points that feed into other metabolites (formate feeding into the folate-dependent pool for example). The key enzymes are ADH, alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; FDH, formaldehyde dehydrogenase (also known as class III alcohol dehydrogenase); FTHFDH, formyltetrahydrofolate dehydrogenase; GO, glycolate oxidase; LDH, lactate dehydrogenase; ?, unknown activity

the end metabolites mediate organ damage. **Methanol** is metabolized to **formic acid**, which produces acidosis as well as retinal and optic nerve damage [34] leading to blindness observed in methanol poisoning. **Ethylene glycol** is metabolized to **glycolic acid**, the major acidic metabolite [35] and then to **oxalic acid**. The latter combines with calcium to form insoluble calcium oxalate monohydrate (COM) which is deposited in the **renal tubules** [5] and causes the **kidney damage** [3]. Diethylene glycol is metabolized to 2-hydroxyethoxyacetic acid (HEAA), which produces the acidosis [36] and then to diglycolic acid, which accumulates in the kidney and is the nephrotoxic metabolite [33, 36]. Because accumulation of metabolites is central to causing toxicity, **inhibition of ADH by competitive substrates like ethanol** or competitive inhibitors of the enzyme like **fomepizole** is the **primary** antidotal **treatment** for metabolically-toxic alcohol poisonings.

Treatment criteria

The traditional **threshold** for initiating ADH inhibitors is **20 mg dl⁻¹ (3 mmol l⁻¹) ethylene glycol, 6 mmol l⁻¹ methanol**, based on anecdotal reports without any apparent justification [37, 38]. The problem with this is that the cut-off for methanol is higher than ethylene glycol,

because toxicity will reflect the potential *levels of toxic metabolite* on a molar per molar basis that could be produced from the alcohol. Assuming there is no or only mild metabolic acidosis (base deficit <10 mmol l⁻¹) and no evidence of organ toxicity on admission, we suggest a cut-off value of 10 mmol l⁻¹ (62 mg dl⁻¹ ethylene glycol, 32 mg dl⁻¹ methanol), which implies 10 mmol l⁻¹ metabolite maximum. The patient should be observed with **repeat analysis of acid base every 2 to 4 h to evaluate potential development of metabolic acidosis**. Key to this recommendation is that patients will typically not have clinical symptoms with formate <8–10 mmol l⁻¹ [9]. Published data are not available for glycolate but are likely similar or even lower. In addition, if patients have blood concentrations <10 mmol l⁻¹, but have symptoms, they should be treated with antidote according to the other treatment criteria (Table 2).

The applicability of osmolal and anion gaps has been questioned because many conditions can increase the gaps [39–45]. However, Aabakken *et al.* [46] have identified a reference value for the osmolal gap to be –9 to 19 mOsm kg⁻¹ H₂O in an emergency department population. By adding a decision level of 25 mOsm kg⁻¹ H₂O, potential false positives are likely to be excluded [8]. Because methanol or ethylene glycol concentrations <20 mmol l⁻¹ (65 or 110 mg dl⁻¹) might not increase the osmolal gap above this reference range [8, 46] and

Table 2**Antidote treatment criteria**.*

Recommended criteria [8]	
I	Serum ethylene glycol or methanol concentration $\geq 10 \text{ mmol l}^{-1}$ (62 mg/dL and 32 mg/dL, respectively)†
II	Documented/suspected recent history of ingestion with an osmolal gap $> 25 \text{ mOsm kg}^{-1} \text{ H}_2\text{O}$ ‡
III	Documented/suspected history of ingestion plus two or more of the following criteria: A: Arterial pH < 7.3 B: Serum bicarbonate $< 20 \text{ mmol l}^{-1}$ C: Osmolal gap $> 25 \text{ mOsm kg}^{-1} \text{ H}_2\text{O}$ ‡ D: Presence of urinary oxalate crystals (ethylene glycol only) or visual disturbances (methanol only)

*Antidote should be given without delay, if toxic alcohol cannot be excluded as the cause. No osmolal gap will be able to exclude toxic alcohol as the cause.

†Only if there is no significant metabolic acidosis (Base deficit $< 10 \text{ mmol l}^{-1}$ (10 mEq)) or no indications of organ toxicity. ‡OG calculated after the ethanol contribution is subtracted.

because formate or glycolate concentrations must increase several times above background levels to significantly increase the anion gap, the sensitivity of these methods is not good at low concentrations [7]. Introducing the new 'decision value' will increase the usefulness of the gaps by increasing the specificity, knowing that a normal gap by itself cannot rule out poisoning in patients with a metabolic acidosis of unknown origin [8].

Although ADH inhibition has also been shown to be therapeutic against diethylene glycol toxicity in animals [47], fomepizole is not approved by the US FDA for this indication nor has ethanol therapy been widely used. Even so, criteria for using these inhibitors in diethylene glycol poisoning are likely to be similar.

Treatment with ethanol

Observing that ethanol consumption often delayed the clinical features of methanol poisoning, Røe [48] postulated that ethanol could be a treatment, along with sodium bicarbonate, for methanol poisoning. The rationale for this treatment is that ethanol has at least 10 times the affinity for ADH compared to methanol [49] and 20-fold more than ethylene glycol [50]. Ethanol occupies the active site of the enzyme, thereby reducing production of toxic metabolites as demonstrated in many case reports/series on methanol or ethylene glycol poisoning [29, 30, 51–53]. Because most patients were also treated with bicarbonate and dialysis, conclusions regarding the efficacy of ethanol therapy alone are limited.

Few reports are available on the use of ethanol as a treatment for diethylene glycol. In one series of five

patients who ingested diethylene glycol, treatment with ethanol and haemodialysis was used, albeit with partial success since there was one fatality and two with renal sequelae after 26 months [54]. Even so, one animal study indicates that ethanol treatment can block the acidosis and renal histopathology produced by a large dose of diethylene glycol (16.8 g kg^{-1}) [55].

Although clinical evidence is lacking for a therapeutic effect of ethanol alone, several studies have demonstrated that ethanol treatment alters the kinetics of toxic alcohols [56, 57]. Because of the extended elimination half-life for the toxic alcohols in patients being treated with ethanol, such studies have led to the recommendation that ethanol therapy needs to be combined with haemodialysis to reduce the length of hospital stay and intensive care time [29].

For therapeutic purposes, a blood ethanol concentration of 100 mg dl^{-1} (22 mmol l^{-1}) is usually recommended, but given the dynamic competition for the enzyme, a molar ratio of 1 : 4 for ethanol is likely sufficient to block metabolism [49]. Nevertheless, the ethanol concentration of 100 mg dl^{-1} has been documented clinically [58] and, since the blood concentration of the metabolically-toxic alcohol is rarely known prior to therapy, an ethanol concentration of 100 mg dl^{-1} is still the recommended target. A standard regimen for achieving the goal of 100 mg dl^{-1} would be giving a bolus dose of 0.6 g kg^{-1} (13 mmol kg^{-1}), followed by maintenance doses from 66 to $154 \text{ mg kg}^{-1} \text{ h}^{-1}$ (1.4 to $3.3 \text{ mmol kg}^{-1} \text{ h}^{-1}$) intravenously or orally (either by drinking or naso-gastric tube), with higher maintenance doses for heavy drinkers (see Table 3 for details) [59]. A convenient formula for calculating the dose in ml of ethanol is:

$$(\text{dose in mg kg}^{-1} \times 0.127 \times \text{bodyweight in kg}) / \times \% \text{alcohol by volume}$$

It is critical that the blood ethanol concentration be measured every 1–2 h to allow for changes in the maintenance infusion, but such analyses are often not available. Haemodialysis removes ethanol in the range of 8.9 – 25 g h^{-1} [29, 56, 60]. An educated estimate is that the maintenance ethanol dose be doubled during intermittent haemodialysis (see Table 3). Alternatively, adding ethanol to the dialysate has been suggested [61–63], but no published data exist on this. During less effective continuous dialysis techniques, it has been estimated that the ethanol infusion only needs to be increased by about 20% [64].

Treatment with fomepizole

Fomepizole (4-methylpyrazole (4MP)) is a potent competitive inhibitor of ADH activity with an affinity more

Table 3

Simplified dosing suggestion for intravenous and oral ethanol treatment for metabolically-toxic alcohol poisonings*

INTRAVENOUS†	iv 5% ethanol	iv 10% ethanol		
Loading dose	15 ml kg ⁻¹	7.5 ml kg ⁻¹		
Infusion rate (not regular drinker)	2–4 ml kg ⁻¹ h ⁻¹	1–2 ml kg ⁻¹ h ⁻¹		
Infusion rate (regular drinker)	4–8 ml kg ⁻¹ h ⁻¹	2–4 ml kg ⁻¹ h ⁻¹		
Infusion rate during HD‡ (not regular drinker)	4–7 ml kg ⁻¹ h ⁻¹	2–3.5 ml kg ⁻¹ h ⁻¹		
Infusion rate during HD‡ (regular drinker)	6–10 ml kg ⁻¹ h ⁻¹	3–5 ml kg ⁻¹ h ⁻¹		
ORAL†	5% ethanol	10% ethanol	20% ethanol	40% ethanol
Loading dose	15 ml kg ⁻¹	7.5 ml kg ⁻¹	4 ml kg ⁻¹	2 ml kg ⁻¹
Drinking dose/h (not regular drinker)	2 ml kg ⁻¹ h ⁻¹	1 ml kg ⁻¹ h ⁻¹	0.5 ml kg ⁻¹ h ⁻¹	0.25 ml kg ⁻¹ h ⁻¹
Drinking dose/h (regular drinker)	4 ml kg ⁻¹ h ⁻¹	2 ml kg ⁻¹ h ⁻¹	1 ml kg ⁻¹ h ⁻¹	0.5 ml kg ⁻¹ h ⁻¹
Drinking dose/h during HD‡ (not regular drinker)	4 ml kg ⁻¹ h ⁻¹	2 ml kg ⁻¹ h ⁻¹	1 ml kg ⁻¹ h ⁻¹	0.5 ml kg ⁻¹ h ⁻¹
Drinking dose/h during HD‡ (regular drinker)	8 ml kg ⁻¹ h ⁻¹	4 ml kg ⁻¹ h ⁻¹	2 ml kg ⁻¹ h ⁻¹	1 ml kg ⁻¹ h ⁻¹

*These suggestions have been adapted from McCoy *et al.* [59] and are only suggestions for the initiation of ethanol treatment. Because of the large inter-individual variability in ethanol metabolism, serum ethanol concentrations should be monitored every 1–2 h if this is available. Effectiveness of blocking can be monitored by analysis of metabolite concentrations (ideally) or of arterial blood gases, if the metabolite and ethanol analyses are not available. †Ethanol can be very irritating, and IV formulations should be diluted with isotonic 5% glucose (dextrose) to a maximum of 10% ethanol-by-volume and administered through a central IV line. If ethanol is administered orally, a 20% or more diluted solution is usually better tolerated. ‡Dialysis (HD) refers to intermittent (high-flow) hemodialysis. During CVVHD, the ethanol increase would be smaller than in table, about 20% above the non-dialysis dose is estimated [64].

than 1000 times that of the toxic alcohols [65]. Fomepizole was shown to reduce the formation of toxic metabolites in lethal methanol and ethylene glycol poisonings in animal models [66, 67]. In these studies, fomepizole reversed an already-developed metabolite accumulation and severe metabolic acidosis without dialysis. The minimum plasma concentration of fomepizole to prevent accumulation of formate was 10 µmol l⁻¹ [68]. In ethylene glycol-poisoned dogs, fomepizole and ethanol decreased the metabolism of ethylene glycol, but ethanol produced a much greater degree of central nervous system (CNS) depression [69].

The pharmacokinetics of fomepizole has been well characterized in animals and humans. Oral fomepizole is rapidly and completely absorbed in humans; T_{max} of 2 h and 100% bioavailability [70–72]. Fomepizole is distributed to total body water and is primarily eliminated by metabolism [69, 70]. In human volunteers, elimination of fomepizole after a single IV dose (5 mg kg⁻¹) shows saturation kinetics, with zero order rate of 4.2 µmol l⁻¹ h⁻¹ [71]. Therefore at therapeutic doses producing blood fomepizole concentrations >10 µmol l⁻¹, fomepizole will have non-linear (“zero order”) elimination kinetics. This has been observed in a methanol-poisoned patient treated with fomepizole (16.9 µmol kg⁻¹ h⁻¹) [73] and in an ethylene glycol-poisoned patient (7.0 µmol kg⁻¹ h⁻¹) [74]. Studies in healthy subjects have indicated that repeated dosing with fomepizole appears to auto-induce its own metabolism after approximately 50 h [71], which is the rationale for the increased fomepizole dose at 48 h.

The dosing schedule for fomepizole is shown in Table 4 [75, 76]. Fomepizole is cleared readily by haemodialysis as shown in animals [77] and poisoned patients [78], so the dosing frequency should be increased during intermittent

and continuous haemodialysis (Table 4). Dosing during continuous dialysis can be less frequent due to the apparently lower extraction of fomepizole of 0.08 reported in an unpublished case, compared to 0.71–0.78 with intermittent haemodialysis [79].

Use of fomepizole and dialysis for methanol poisoning

Methanol is primarily cleared by metabolism, so its half-life during fomepizole therapy is increased (50–80 h) [80]. Haemodialysis is often used to shorten the duration of therapy and hospital stay [81–83], and intermittent haemodialysis has been shown to be superior to continuous dialysis modalities [78]. Previous recommendations used ≥50 mg/dL (15.6 mmol l⁻¹) as a threshold for haemodialysis in fomepizole-treated patients or if the patient displayed visual loss or severe metabolic acidosis [84]. However, it has been suggested [32, 82, 83, 85], and also shown [86], that fomepizole can postpone or ameliorate dialysis and methanol concentrations >50 mg/dL (15.6 mmol l⁻¹) have been successfully treated with only fomepizole [21, 80, 87, 88]. Hence, the use of haemodialysis should depend on the patient condition and not on methanol concentration *per se*.

Use of fomepizole and dialysis for ethylene glycol poisoning

Unlike methanol, ethylene glycol is substantially cleared by the kidneys (half-life about 16 h during fomepizole treatment) [21, 87, 88]. Thus, even with metabolic inhibition, most of the ethylene glycol can be eliminated by functional kidneys. Similar to methanol a ≥ 50 mg/dL (8.1 mmol l⁻¹) cut-off has been used for ethylene glycol, but again patients with concentrations above this have been treated with fomepizole alone. There have been

Table 4

Simplified dosing suggestion for fomepizole treatment for metabolically-toxic alcohol poisonings

No dialysis		Loading dose Maintenance dose	15 mg kg ⁻¹ (Dose 1)	
			10 mg kg ⁻¹ every 12 h (Dose 2–4)	15 mg kg ⁻¹ every 12 h (Dose 5-onwards)
During dialysis	IHD [75, 76]	Maintenance dose during IHD	10 mg kg ⁻¹ every 4 h	
			or	
		Maintenance continuous dose during IHD	1 mg kg ⁻¹ h ⁻¹	
	CVVHD (unpublished data)	Maintenance dose during CVVHD	10 mg kg ⁻¹ every 8 h	
			or	
		Maintenance continuous dose during CVVHD	0.5 mg kg ⁻¹ h ⁻¹	

cases with extreme ethylene glycol concentrations (>1000 mg/dL, 161 mmol l⁻¹), where dialysis was claimed to be needed to avoid complications related to hyperosmolality [89].

Use of fomepizole for diethylene glycol poisoning

Fomepizole blocks the acidosis and organ toxicity (liver and kidney) produced by diethylene glycol in rats [47]. There are a small number of reports of successful fomepizole treatment in humans with diethylene glycol poisoning [90–92]. However, treatment of diethylene glycol poisoning is not an FDA-approved indication for fomepizole.

Comparison of fomepizole and ethanol

Efficacy (ability to reverse toxic alcohol effects)

Both antidotes have a stronger affinity for ADH than the toxic alcohols, but fomepizole has a much higher affinity for the enzyme compared to ethanol (>80 000 versus 10 times stronger than methanol) [93]. Fomepizole binds to the active site competitively, while ethanol itself is metabolized by ADH, thus competes only transiently for the active site. These characteristics favour the efficacy of fomepizole over ethanol. Unfortunately, the prospective clinical trials of fomepizole [75, 76] did not compare it with ethanol and were not able to distinguish the role of antidote therapy from the role of haemodialysis. It is highly unlikely that randomized control trials will be done, because of ethical issues, the infrequency of poisoning and outbreaks, and the lack of facilities for in-depth studies in the developing world where outbreaks usually occur. Comparing survival, either prospectively or retrospectively, between different outbreaks is problematic because of the variable reporting of the number of victims and fatalities, uncertain times from intake to treatment, lack of analytical data, variable toxic alcohol and ethanol concentrations in the toxic liquor and uneven reporting of history of ingestion.

Two large studies have tried to compare the effects of ethanol and fomepizole [94, 95]. Although Paasma and

coworkers did not find a significantly better overall outcome with fomepizole, methanol-poisoned patients that could hyperventilate had a significantly better survival with fomepizole compared to ethanol [95]. No difference in outcome between ethanol and fomepizole was found in the study by Zakharov *et al.* [84], who did a pairwise comparison to evaluate outcome parameters. These patients had similar treatments except for the antidote, supporting ethanol as an equitable antidote given ideal circumstances.

Efficiency (practicality of use)

As noted in Table 5, various elements make fomepizole theoretically superior to ethanol in terms of practical use. A major problem with ethanol therapy is the difficulty in maintaining recommended therapeutic concentrations, because of the huge variability in ethanol elimination rates and its rapid elimination during dialysis [96, 97]. Sufficient ethanol concentrations are best maintained by frequent measurements (every 1–2 h) and dose adjustments. However, ethanol analyses need to be available which is not the case in many areas especially the developing world [19]. Zakharov [97] monitored serum ethanol concentrations for 90 ± 20 (SD) hours in 21 methanol-poisoned patients treated with ethanol. Concentrations were in the therapeutic range (100–150 mg/dL, 22–33 mmol l⁻¹) 28% of the time, above the range 29% of the time (peaking at 350 mg/dL (76 mmol l⁻¹)) and sub-therapeutic 44% of the time.

Another problem with ethanol is the potential for adverse effects, especially CNS depression. In a methanol outbreak, Paasma *et al.* [15] found that 40% of patients who were awake on admission became comatose within one hour of ethanol treatment. In a retrospective review of adverse events in methanol and ethylene glycol-poisoned cases, CNS symptoms were reported in half of the cases treated with ethanol, while only in 2% treated with fomepizole [98]. Zakharov *et al.* reported that 48% of patients treated with ethanol developed severe intoxication, but did not become comatose, most likely because of the close monitoring of patients given ethanol [16].

Table 5

Ethanol versus fomepizole

	Ethanol	Fomepizole
Availability	Good (especially orally)	Limited (especially in the developing world)
Cost	Low (in most countries)	High
Practical use	Difficult to keep at therapeutic level, especially during HD	Easy to administer, also during HD
Monitoring of serum concentrations	Necessary	Not necessary
CNS-depressive	Yes	No
Need for HD	Yes	May be avoided or postponed
Need for ICU	Yes	May be avoided

HD, haemodialysis; ICU, intensive care unit.

Although hypoglycemia is a potential risk in children treated with ethanol [98], this has not been observed with toxic alcohol poisoning, most likely because ethanol is infused in a dextrose solution. In a retrospective review of paediatric patients, Roy *et al.* reported that none had any signs of hypoglycemia and only 16% had a serum glucose concentration between 2.8 and 3.6 mmol l⁻¹ (50 and 65 mg/dL) [99]. Hypoglycemia is not likely with fomepizole [90, 100, 101].

In pregnant women, both ethanol and fomepizole have been used to treat toxic alcohol ingestions [102, 103]. In a study of pregnant rats, no adverse effects to fomepizole were reported [104], and no similar study exists for ethanol. In a pregnant woman with severe metabolically-toxic alcohol poisoning, an antidote is obligatory, and if fomepizole is not available, ethanol should be used.

Although fomepizole is generally well tolerated in humans, occasional adverse effects such as nausea or dizziness have been reported, with uncertain causality. The only contraindication to fomepizole is a previous allergic reaction to methylpyrazoles, although this has not been reported.

Combination with haemodialysis

Fomepizole appears to reduce the need for haemodialysis, at least in ethylene glycol exposures. This is because of the well-defined kinetics and simple dosing of fomepizole, allowing haemodialysis to be postponed or omitted in specific cases, particularly if there is limited availability of dialysis [75, 82, 83, 86, 88, 105, 106]. The use of fomepizole simplifies management of many patients, and potentially reduces the use of intensive care beds [14, 15, 19].

Cost-benefit

Fomepizole costs more than ethanol in most countries, but an accurate cost comparison needs to include intensive care expenses, need for nursing care and requirement for blood ethanol monitoring [107]. All these costs are country-dependent [108]. The cost of fomepizole therapy may be greater with methanol-poisoned patients than with

ethylene glycol-poisoned patients due to the lengthy elimination of methanol during ADH inhibition. In the US and in Norway (personal communication), the costs of ethanol for IV use and of generic fomepizole are similar [32]. Fomepizole is now on the World Health Organisation List of Essential Medicines [109], which is likely to increase the worldwide availability, hopefully to be followed by a lower price.

Conclusions

Guidelines suggest that fomepizole should be the main antidote for methanol or ethylene glycol poisoning [37, 38], while ethanol can be used when fomepizole is unavailable. The preference for fomepizole in most countries is based on its efficacy and lower degree of adverse effects compared with ethanol, [95, 108] and its major drawback is the perceived high cost.

Competing Interests

All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf. Drs. Hovda and Jacobsen declare no support from any organisation for the submitted work. Dr. McMartin had no support from any organization for the submitted work, but reports Other from Mericon Investment group, outside the submitted work.

The authors would like to thank Ashton Jorgensen for creating the figure for this manuscript and Yvonne Lao RPh for verifying the dosing recommendations.

REFERENCES

- 1 Paasma R, Hovda KE, Jacobsen D. Methanol poisoning and long term sequelae - a six years follow-up after a large methanol outbreak. *BMC Clin Pharmacol* 2009; 9:5.: 5.
- 2 Zakharov S, Pelclova D, Diblik P, Urban P, Kuthan P, Nurieva O, Kotikova K, Navratil T, Komarc M, Belacek J, Seidl Z,

- Vaneckova M, Hubacek JA, Bezdicek O, Klempir J, Yurchenko M, Ruzicka E, Miovsky M, Janikova B, Hovda KE. Long-term visual damage after acute methanol poisonings: longitudinal cross-sectional study in 50 patients. *Clin Toxicol (Phila)* 2015; 53: 884–92.
- 3 McMartin K. Are calcium oxalate crystals involved in the mechanism of acute renal failure in ethylene glycol poisoning? *Clin Toxicol (Phila)* 2009; 47: 859–69.
- 4 Conklin L, Sejvar JJ, Kieszak S, Sabogal R, Sanchez C, Flanders D, Tulloch F, Victoria G, Rodriguez G, Sosa N, McGeehin MA, Schier JG. Long-term renal and neurologic outcomes among survivors of diethylene glycol poisoning. *JAMA Intern Med* 2014; 174: 912–7.
- 5 Hovda KE, Guo C, Austin R, McMartin KE. Renal toxicity of ethylene glycol results from internalization of calcium oxalate crystals by proximal tubule cells. *Toxicol Lett* 2010; 192: 365–72.
- 6 Sosa NR, Rodriguez GM, Schier JG, Sejvar JJ. Clinical, laboratory, diagnostic, and histopathologic features of diethylene glycol poisoning--panama, 2006. *Ann Emerg Med* 2014; 64: 38–47.
- 7 Kraut JA. Diagnosis of toxic alcohols: limitations of present methods. *Clin Toxicol (Phila)* 2015; 53: 589–95.
- 8 Hovda KE, Hunderi OH, Rudberg N, Froyshov S, Jacobsen D. Anion and osmolal gaps in the diagnosis of methanol poisoning: clinical study in 28 patients. *Intensive Care Med* 2004; 30: 1842–6.
- 9 Hovda KE, Urdal P, Jacobsen D. Increased serum formate in the diagnosis of methanol poisoning. *J Anal Toxicol* 2005; 29: 586–8.
- 10 Hovda KE, Gadeholt G, Evtodienko V, Jacobsen D. A novel bedside diagnostic test for methanol poisoning using dry chemistry for formate. *Scand J Clin Lab Invest* 2015; 75: 610–4.
- 11 Mowry JB, Spyker DA, Cantilena LR Jr, McMillan N, Ford M. 2013 annual report of the american association of poison control centers' national Poison data system (NPDS): 31st Annual Report. *Clin Toxicol (Phila)* 2014; 52: 1032–283.
- 12 Litovitz TL, Schmitz BF, Matyunas N, Martin TG. 1987 annual report of the American Association of Poison Control Centers National Data collection System. *Am J Emerg Med* 1988; 6: 479–515.
- 13 Recent outbreaks of methanol poisonings - an overview. In, [http://www.oslo-universitetssykehus.no/omoss_/avdelinger/_akuttmedisinsk/Documents/outbreaks new table combined.pdf](http://www.oslo-universitetssykehus.no/omoss_/avdelinger/_akuttmedisinsk/Documents/outbreaks%20new%20table%20combined.pdf) (last accessed 5 October 2015).
- 14 Hovda KE, Hunderi OH, Tafjord AB, Dunlop O, Rudberg N, Jacobsen D. Methanol outbreak in Norway 2002–2004: epidemiology, clinical features and prognostic signs. *J Intern Med* 2005; 258: 181–90.
- 15 Paasma R, Hovda KE, Tikkerberi A, Jacobsen D. Methanol mass poisoning in Estonia: Outbreak in 154 patients. *Clin Toxicol (Phila)* 2007; 45: 152–7.
- 16 Zakharov S, Pelclova D, Urban P, Navratil T, Diblik P, Kuthan P, Hubacek JA, Miovsky M, Klempir J, Vaneckova M, Seidl Z, Pilin A, Fenclova Z, Petrik V, Kotikova K, Nurieva O, Ridzon P, Rulisek J, Komarc M, Hovda KE. Czech mass methanol outbreak 2012: Epidemiology, challenges and clinical features. *Clin Toxicol (Phila)* 2014; 52: 1013–24.
- 17 Ahmad K. Methanol-laced moonshine kills 140 in Kenya. *Lancet* 2000; 356: 1911.
- 18 Levy P, Hexdall A, Gordon P, Boeriu C, Heller M, Nelson L. Methanol contamination of Romanian home-distilled alcohol. *J Toxicol Clin Toxicol* 2003; 41: 23–8.
- 19 Hassanian-Moghaddam H, Nikfarjam A, Mirafzal A, Saberinia A, Nasehi AA, Masoumi Asl H, Memaryan N. Methanol mass poisoning in Iran: role of case finding in outbreak management. *J Public Health (Oxf)* 2015 37; 354–9.
- 20 AbdulRahim FAA, Shiekh AA. Substance abuse and homeless: mass methanol poisoning in Khartoum. *Sudan Med J* 2012; 48: 1–5.
- 21 Hovda KE, Julsrud J, Ovrebø S, Brors O, Jacobsen D. Studies on ethylene glycol poisoning: One patient - 154 admissions. *Clin Toxicol (Phila)* 2011; 49: 478–84.
- 22 2 Mo. women charged in antifreeze poisoning deaths. In, <http://www.usatoday.com/story/news/nation/2013/06/23/antifreeze-deaths/2449915/> (last accessed 12 September 2015).
- 23 Karlson-Stiber C, Persson H. Ethylene glycol poisoning: experiences from an epidemic in Sweden. *J Toxicol Clin Toxicol* 1992; 30: 565–74.
- 24 Walton EW. An epidemic of antifreeze poisoning. *Med Sci Law* 1978; 18: 231–7.
- 25 Schier JG, Rubin CS, Miller D, Barr D, McGeehin MA. Medication-associated diethylene glycol mass poisoning: a review and discussion on the origin of contamination. *J Public Health Policy* 2009; 30: 127–43.
- 26 Schep LJ, Slaughter RJ, Temple WA, Beasley DM. Diethylene glycol poisoning. *Clin Toxicol (Phila)* 2009; 47: 525–35.
- 27 O'Brien KL, Selanikio JD, Heccdivert C, Placide MF, Louis M, Barr DB, Barr JR, Hospedales CJ, Lewis MJ, Schwartz B, Philen RM, St Victor S, Espindola J, Needham LL, Denerville K. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. Acute Renal Failure Investigation Team. *JAMA* 1998; 279: 1175–80.
- 28 Rentz ED, Lewis L, Mujica OJ, Barr DB, Schier JG, Weerasekera G, Kuklenyik P, McGeehin M, Osterloh J, Wamsley J, Lum W, Alleyne C, Sosa N, Motta J, Rubin C. Outbreak of acute renal failure in Panama in 2006: a case-control study. *Bull World Health Organ* 2008; 86: 749–56.
- 29 Jacobsen D, Jansen H, Wiik-Larsen E, Bredesen JE, Halvorsen S. Studies on methanol poisoning. *Acta Med Scand* 1982; 212: 5–10.
- 30 Jacobsen D, Ostby N, Bredesen JE. Studies on ethylene glycol poisoning. *Acta Med Scand* 1982; 212: 11–5.
- 31 Krishnamurthi MV, Natarajan AR, Shanmugasundaram K, Padmanabhan K, Nityanandan K. Acute methyl alcohol poisoning. (A review of an outbreak of 89 cases). *J Assoc Physicians India* 1968; 16: 801–5.

- 32 Brent J. Fomepizole for ethylene glycol and methanol poisoning. *N Engl J Med* 2009; 360: 2216–23.
- 33 Landry GM, Martin S, McMartin KE. Diglycolic acid is the nephrotoxic metabolite in diethylene glycol poisoning inducing necrosis in human proximal tubule cells in vitro. *Toxicol Sci* 2011; 124: 35–44.
- 34 Martin-Amat G, McMartin KE, Hayreh SS, Hayreh MS, Tephly TR. Methanol poisoning: ocular toxicity produced by formate. *Toxicol Appl Pharmacol* 1978; 45: 201–8.
- 35 Jacobsen D, Ovrebo S, Ostborg J, Sejersted OM. Glycolate causes the acidosis in ethylene glycol poisoning and is effectively removed by hemodialysis. *Acta Med Scand* 1984; 216: 409–16.
- 36 Besenhofer LM, McLaren MC, Latimer B, Bartels M, Filary MJ, Perala AW, McMartin KE. Role of tissue metabolite accumulation in the renal toxicity of diethylene glycol. *Toxicol Sci* 2011; 123: 374–83.
- 37 Barceloux DG, Bond GR, Krenzelok EP, Cooper H, Vale JA, American Academy of Clinical Toxicology Ad Hoc Committee on the Treatment Guidelines for Methanol P. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. *J Toxicol Clin Toxicol* 2002; 40: 415–46.
- 38 Barceloux DG, Krenzelok EP, Olson K, Watson W. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. *J Toxicol Clin Toxicol* 1999; 37: 537–60.
- 39 Hoffman RS, Smilkstein MJ, Howland MA, Goldfrank LR. Osmol gaps revisited: normal values and limitations. *J Toxicol Clin Toxicol* 1993; 31: 81–93.
- 40 Sulway MJ, Malins JM. Acetone in diabetic ketoacidosis. *Lancet* 1970; 2: 736–40.
- 41 Cooperman MT, Davidoff F, Spark R, Pallotta J. Clinical studies of alcoholic ketoacidosis. *Diabetes* 1974; 23: 433–9.
- 42 Almaghamsi AM, Yeung CK. Osmolal gap in alcoholic ketoacidosis. *Clin Nephrol* 1997; 48: 52–3.
- 43 Schelling JR, Howard RL, Winter SD, Linas SL. Increased osmolal gap in alcoholic ketoacidosis and lactic acidosis. *Ann Intern Med* 1990; 113: 580–2.
- 44 Sklar AH, Linas SL. The osmolal gap in renal failure. *Ann Intern Med* 1983; 98: 481–2.
- 45 Boyd DR, Folk FA, Condon RE, Nyhus LM, Baker RJ. Predictive value of serum osmolality in shock following major trauma. *Surg Forum* 1970; 21: 32–3.
- 46 Aabakken L, Johansen KS, Rydningen EB, Bredesen JE, Ovrebo S, Jacobsen D. Osmolal and anion gaps in patients admitted to an emergency medical department. *Hum Exp Toxicol* 1994; 13: 131–4.
- 47 Besenhofer LM, Adegboyega PA, Bartels M, Filary MJ, Perala AW, McLaren MC, McMartin KE. Inhibition of metabolism of diethylene glycol prevents target organ toxicity in rats. *Toxicol Sci* 2010; 117: 25–35.
- 48 Roe O. Clinical investigations of methyl alcohol poisoning with special references to the pathogenesis and treatment of amblyopia. *Acta Med Scand* 1943; 63: 558–605.
- 49 Makar AB, Tephly TR, Mannering GJ. Methanol metabolism in the monkey. *Mol Pharmacol* 1968; 4: 471–83.
- 50 Weiss B, Coen G. Effect of ethanol on ethylene glycol oxidation by mammalian liver enzymes. *Enzymol Biol Clin (Basel)* 1966; 6: 297–304.
- 51 Swartz RD, Millman RP, Billi JE, Bondar NP, Migdal SD, Simonian SK, Monforte JR, McDonald FD, Harness JK, Cole KL. Epidemic methanol poisoning: clinical and biochemical analysis of a recent episode. *Medicine (Baltimore)* 1981; 60: 373–82.
- 52 Malmund HO, Berg A, Karlman G, Magnusson A, Ullman B. Considerations for the treatment of ethylene glycol poisoning based on analysis of two cases. *J Toxicol Clin Toxicol* 1991; 29: 231–40.
- 53 Ekins BR, Rollins DE, Duffy DP, Gregory MC. Standardized treatment of severe methanol poisoning with ethanol and hemodialysis. *West J Med* 1985; 142: 337–40.
- 54 Alfred S, Coleman P, Harris D, Wigmore T, Stachowski E, Graudins A. Delayed neurologic sequelae resulting from epidemic diethylene glycol poisoning. *Clin Toxicol (Phila)* 2005; 43: 155–9.
- 55 Hebert JL, Farbe M, Auzepy P, Pailas J. Acute experimental poisoning by diethylene glycol: acid base balance and histological data in male rats. *Toxicol Eur Res* 1978; 1: 289–94.
- 56 Peterson CD, Collins AJ, Himes JM, Bullock ML, Keane WF. Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. *N Engl J Med* 1981; 304: 21–3.
- 57 Palatnick W, Redman LW, Sitar DS, Tenenbein M. Methanol half-life during ethanol administration: implications for management of methanol poisoning. *Ann Emerg Med* 1995; 26: 202–7.
- 58 Jacobsen D, Ovrebo S, Arnesen E, Paus PN. Pulmonary excretion of methanol in man. *Scand J Clin Lab Invest* 1983; 43: 377–9.
- 59 McCoy HG, Cipolle RJ, Ehlers SM, Sawchuk RJ, Zaske DE. Severe methanol poisoning. Application of a pharmacokinetic model for ethanol therapy and hemodialysis. *Am J Med* 1979; 67: 804–7.
- 60 Gonda A, Gault H, Churchill D, Hollomby D. Hemodialysis for methanol intoxication. *Am J Med* 1978; 64: 749–58.
- 61 Chow MT, Di SV, Yung CY, Nawab ZM, Leehey DJ, Ing TS. Treatment of acute methanol intoxication with hemodialysis using an ethanol-enriched, bicarbonate-based dialysate. *Am J Kidney Dis* 1997; 30: 568–70.
- 62 Dorval M, Pichette V, Cardinal J, Geadah D, Quimet D, Leblanc M. The use of an ethanol- and phosphate-enriched dialysate to maintain stable serum ethanol levels during haemodialysis for methanol intoxication. *Nephrol Dial Transplant* 1999; 14: 1774–7.

- 63** Noghnogh AA, Reid RW, Nawab ZM, Swartz RD, Kjellstrand CM, Ing TS. Preparation of ethanol-enriched, bicarbonate-based hemodialysates. *Artif Organs* 1999; 23: 208–9.
- 64** Coulter CV, Isbister GK, Duffull SB. The pharmacokinetics of methanol in the presence of ethanol: a case study. *Clin Pharmacokinet* 2011; 50: 245–51.
- 65** Li TK, Theorell H. Human liver alcohol dehydrogenase: inhibition by pyrazole and pyrazole analogs. *Acta Chem Scand A* 1969; 23: 892–902.
- 66** McMartin KE, Makar AB, Martin G, Palese M, Tephly TR. Methanol poisoning. I. The role of formic acid in the development of metabolic acidosis in the monkey and the reversal by 4-methylpyrazole. *Biochem Med* 1975; 13: 319–33.
- 67** Clay KL, Watkins WD, Murphy RC. Metabolism of pyrazole. Structure elucidation of urinary metabolites. *Drug Metab Dispos* 1977; 5: 149–56.
- 68** McMartin KE, Hedstrom KG, Tolf BR, Ostling-Wintzell H, Blomstrand R. Studies on the metabolic interactions between 4-methylpyrazole and methanol using the monkey as an animal model. *Arch Biochem Biophys* 1980; 199: 606–14.
- 69** Grauer GF, Thrall MA, Henre BA, Hjelle JJ. Comparison of the effects of ethanol and 4-methylpyrazole on the pharmacokinetics and toxicity of ethylene glycol in the dog. *Toxicol Lett* 1987; 35: 307–14.
- 70** Jacobsen D, Barron SK, Sebastian CS, Blomstrand R, McMartin KE. Non-linear kinetics of 4-methylpyrazole in healthy human subjects. *Eur J Clin Pharmacol* 1989; 37: 599–604.
- 71** McMartin KE, Sebastian CS, Dies D, Jacobsen D. Kinetics and metabolism of fomepizole in healthy humans. *Clin Toxicol (Phila)* 2012; 50: 375–83.
- 72** Marraffa JF, McMartin KE, Forrest A, Howland MA, Grant W, Stork CM. Oral administration of fomepizole produces similar blood levels as identical intravenous dose. *Clin Toxicol (Phila)* 2008; 46: 181–6.
- 73** Hovda KE, Mundal H, Urdal P, McMartin K, Jacobsen D. Extremely slow formate elimination in severe methanol poisoning: a fatal case report. *Clin Toxicol (Phila)* 2007; 45: 516–21.
- 74** Vu BD, Crouzier C, Hubert I, Galliot M, Baud FJ, Bourdon R. Etude analytique et pharmacocinetique du 4-methylpyrazole, nouvel antidote pour le traitement de l'intoxication a l'ethylene glycol. *Ann Fais Exp Chim* 1992; 85: 99–110.
- 75** Brent J, McMartin K, Phillips S, Aaron C, Kulig K, Methylpyrazole for Toxic Alcohols Study G. Fomepizole for the treatment of methanol poisoning. *N Engl J Med* 2001; 344: 424–9.
- 76** Brent J, McMartin K, Phillips S, Burkhart KK, Donovan JW, Wells M, Kulig K. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. *N Engl J Med* 1999; 340: 832–8.
- 77** Jacobsen D, Ostensen J, Bredesen L, Ullstein E, McMartin K. 4-Methylpyrazole (4-MP) is effectively removed by haemodialysis in the pig model. *Hum Exp Toxicol* 1996; 15: 494–6.
- 78** Zakharov S, Pelclova D, Navratil T, Belacek J, Kurcova I, Komzak O, Salek T, Latta J, Turek R, Bocek R, Kucera C, Hubacek JA, Fenclova Z, Petrik V, Cermak M, Hovda KE. Intermittent hemodialysis is superior to continuous veno-venous hemodialysis/hemodiafiltration to eliminate methanol and formate during treatment for methanol poisoning. *Kidney Int* 2014; 86: 199–207.
- 79** Faessel H, Houze P, Baud FJ, Scherrmann JM. 4-methylpyrazole monitoring during haemodialysis of ethylene glycol intoxicated patients. *Eur J Clin Pharmacol* 1995; 49: 211–3.
- 80** Hovda KE, Andersson KS, Urdal P, Jacobsen D. Methanol and formate kinetics during treatment with fomepizole. *Clin Toxicol* 2005; 43: 221–7.
- 81** Roberts DM, Yates C, Megarbane B, Winchester JF, Maclaren R, Gosselin S, Nolin TD, Lavergne V, Hoffman RS, Ghannoum M. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement. *Crit Care Med* 2015; 43: 461–72.
- 82** Hovda KE, Jacobsen D. Expert opinion: fomepizole may ameliorate the need for hemodialysis in methanol poisoning. *Hum Exp Toxicol* 2008; 27: 539–46.
- 83** Megarbane B, Borron SW, Baud FJ. Current recommendations for treatment of severe toxic alcohol poisonings. *Intensive Care Med* 2005; 31: 189–95.
- 84** Zakharov S, Pelclova D, Navratil T, Belacek J, Komarc M, Eddleston M, Hovda KE. Fomepizole versus ethanol in the treatment of acute methanol poisoning: Comparison of clinical effectiveness in a mass poisoning outbreak. *Clin Toxicol (Phila)* 2015; 53: 797–806.
- 85** Megarbane B, Borron SW, Trout H, Hantson P, Jaeger A, Krencker E, Bismuth C, Baud FJ. Treatment of acute methanol poisoning with fomepizole. *Intensive Care Med* 2001; 27: 1370–8.
- 86** Hovda KE, Froyshov S, Gudmundsdottir H, Rudberg N, Jacobsen D. Fomepizole may change the indication for HD in methanol poisoning: Prospective study in 7 cases. *Clin Nephrol* 2005; 64: 190–7.
- 87** Aakervik O, Svendsen J, Jacobsen D. Severe ethylene glycol poisoning treated with fomepizole (4-methylpyrazole). *Tidsskr Nor Laegeforen* 2002; 122: 2444–6.
- 88** Buchanan JA, Alhelail M, Cetaruk EW, Schaeffer TH, Palmer RB, Kulig K, Brent J. Massive ethylene glycol ingestion treated with fomepizole alone—a viable therapeutic option. *J Med Toxicol* 2010; 6: 131–4.
- 89** Ahmed A, Tschetter PA, Krasowski MD, Engelman A. Massive ethylene glycol poisoning triggers osmotic demyelination syndrome. *J Emerg Med* 2014; 46: e69–74.
- 90** Brophy PD, Tenenbein M, Gardner J, Bunchman TE, Smoyer WE. Childhood diethylene glycol poisoning treated with

- alcohol dehydrogenase inhibitor fomepizole and hemodialysis. *Am J Kidney Dis* 2000; 35: 958–62.
- 91 Borron SW, Baud FJ, Garnier R. Intravenous 4-methylpyrazole as an antidote for diethylene glycol and triethylene glycol poisoning: a case report. *Vet Hum Toxicol* 1997; 39: 26–8.
 - 92 Rollins YD, Filley CM, McNutt JT, Chahal S, Kleinschmidt-DeMasters BK. Fulminant ascending paralysis as a delayed sequela of diethylene glycol (Sterno) ingestion. *Neurology* 2002; 59: 1460–3.
 - 93 Bestic M, Blackford M, Reed M. Fomepizole: A critical assessment of current dosing recommendations. *J Clin Pharmacol* 49: 130–37.
 - 94 Zakharov S, Pelclova D, Urban P, Navratil T, Diblik P, Kuthan P, Hubacek JA, Miovsy M, Klempir J, Vaneckova M, Seidl Z, Pilin A, Fenclova Z, Petrik V, Kotikova K, Nurieva O, Ridzon P, Rulisek J, Komarc M, Hovda KE. Czech mass methanol outbreak 2012: epidemiology, challenges and clinical features. *Clin Toxicol (Phila)* 2014; 52: 1013–24.
 - 95 Paasma R, Hovda KE, Hassanian-Moghaddam H, Brahmi N, Afshari R, Sandvik L, Jacobsen D. Risk factors related to poor outcome after methanol poisoning and the relation between outcome and antidotes--a multicenter study. *Clin Toxicol (Phila)* 2012; 50: 823–31.
 - 96 Hantson P, Wittebole X, Haufrond V. Ethanol therapy for methanol poisoning: duration and problems. *Eur J Emerg Med* 2002; 9: 278–9.
 - 97 Zakharov S, Navratil T, Salek T, Kurcova I, Pelclova D. Fluctuations in serum ethanol concentration in the treatment of acute methanol poisoning: a prospective study of 21 patients. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2015. [Epub ahead of print]
 - 98 Lepik KJ, Levy AR, Sobolev BG, Purssell RA, DeWitt CR, Erhardt GD, Kennedy JR, Daws DE, Brignall JL. Adverse drug events associated with the antidotes for methanol and ethylene glycol poisoning: a comparison of ethanol and fomepizole. *Ann Emerg Med* 2009; 53: 439–50.
 - 99 Roy M, Bailey B, Chalut D, Senecal PE, Gaudreault P. What are the adverse effects of ethanol used as an antidote in the treatment of suspected methanol poisoning in children? *J Toxicol Clin Toxicol* 2003; 41: 155–61.
 - 100 Brent J. Fomepizole for the treatment of pediatric ethylene and diethylene glycol, butoxyethanol, and methanol poisonings. *Clin Toxicol (Phila)* 2010; 48: 401–6.
 - 101 Brown MJ, Shannon MW, Woolf A, Boyer EW. Childhood methanol ingestion treated with fomepizole and hemodialysis. *Pediatrics* 2001; 108: E77.
 - 102 Hantson P, Lambermont JY, Mahieu P. Methanol poisoning during late pregnancy. *J Toxicol Clin Toxicol* 1997; 35: 187–91.
 - 103 Velez LI, Kulstad E, Shepherd G, Roth B. Inhalational methanol toxicity in pregnancy treated twice with fomepizole. *Vet Hum Toxicol* 2003; 45: 28–30.
 - 104 Gracia R, Latimer B, McMartin KE. Kinetics of fomepizole in pregnant rats. *Clin Toxicol (Phila)* 2012; 50: 743–8.
 - 105 Caravati EM, Heilesen HL, Jones M. Treatment of severe pediatric ethylene glycol intoxication without hemodialysis. *J Toxicol Clin Toxicol* 2004; 42: 255–9.
 - 106 Borron SW, Megarbane B, Baud FJ. Fomepizole in treatment of uncomplicated ethylene glycol poisoning. *Lancet* 1999; 354: 831.
 - 107 Sivilotti ML. Ethanol: tastes great! Fomepizole: less filling! *Ann Emerg Med* 2009; 53: 451–3.
 - 108 Beatty L, Green R, Magee K, Zed P. A systematic review of ethanol and fomepizole use in toxic alcohol ingestions. *Emerg Med Int* 2013; 2013: 638057.
 - 109 WHO - Essential Medicines List 2013. In, http://www.who.int/medicines/publications/essentialmedicines/18th_EML_Final_web_8Jul13.pdf (last accessed 15 May 2015).